Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism—neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.
Current treatments centre on the management of dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the Parkinson’s market for the past half century. These therapies provide the best relief of symptoms at a low annual cost of therapy (ACOT), with Sinemet (carbidopa/levodopa) and Madopar (benserazide/levodopa) being the two most popular branded drugs.
GlobalData estimates that drug sales for PD in 2016 were approximately $3.1B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $8.8B at a CAGR of 11.1%. This growth will be driven by the launch of thirteen late-stage pipeline products. The two highest selling drugs are expected to be Roche/Prothena’s PRX-002and Acorda’s CVT-301, which both address some of the unmet needs in the market.
Key Questions Answered
What are the key PD treatments in 2016?
When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?
Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?
Scope
Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2016 to 2026.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase III development are profiled.
Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Roche
Prothena
Acorda Therapeutics
Voyager Therapeutics
Impax Pharmaceuticals
UCB
AbbVie
Novartis
Orion Pharmaceuticals
Intec Pharma
NeuroDerm
Adamas Therapeutics
Acadia
Sunovion
Roche
MSD
GSK
Britannia Pharmaceuticals
Novo Nordisk
Integrative Research Laboratories (IRLAB)
Lundbeck
US WorldMeds
Zambon
Eisai
Meiji Seika
Addex Therapeutics
Sanofi
Neurocrine Biosciences
Ono Pharmaceuticals
Otsuka Pharmaceutical
Takeda
Bial
Newron
Kyowa Hakko Kirin
Genzyme
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.